Public Employees Retirement System of Ohio Decreases Stock Position in Enovis Corporation $ENOV

Public Employees Retirement System of Ohio lessened its stake in Enovis Corporation (NYSE:ENOV) by 23.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 55,142 shares of the company’s stock after selling 17,207 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.10% of Enovis worth $1,729,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. US Bancorp DE boosted its holdings in Enovis by 2.5% in the 1st quarter. US Bancorp DE now owns 19,031 shares of the company’s stock worth $727,000 after acquiring an additional 462 shares during the period. Central Valley Advisors LLC boosted its stake in shares of Enovis by 18.5% during the 2nd quarter. Central Valley Advisors LLC now owns 57,372 shares of the company’s stock valued at $1,799,000 after buying an additional 8,951 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Enovis during the 1st quarter valued at approximately $537,000. Cubist Systematic Strategies LLC boosted its stake in shares of Enovis by 431.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 116,592 shares of the company’s stock valued at $4,455,000 after buying an additional 94,670 shares during the last quarter. Finally, Louisiana State Employees Retirement System boosted its stake in shares of Enovis by 72.9% during the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the company’s stock valued at $1,024,000 after buying an additional 11,300 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on ENOV. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovis in a research note on Saturday, September 27th. Canaccord Genuity Group reduced their target price on Enovis from $70.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Evercore ISI reduced their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. UBS Group reduced their target price on Enovis from $65.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Wells Fargo & Company reduced their target price on Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Insider Activity

In other Enovis news, CEO Damien Mcdonald purchased 6,457 shares of the stock in a transaction dated Thursday, September 11th. The shares were bought at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the acquisition, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This trade represents a 6.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Bradley J. Tandy purchased 3,200 shares of the stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the acquisition, the senior vice president directly owned 43,515 shares of the company’s stock, valued at approximately $1,366,806.15. This trade represents a 7.94% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 12,157 shares of company stock valued at $374,760. Company insiders own 2.70% of the company’s stock.

Enovis Price Performance

Shares of NYSE ENOV opened at $32.02 on Friday. The firm has a market capitalization of $1.83 billion, a PE ratio of -2.25 and a beta of 1.69. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.83. The business’s fifty day moving average price is $30.09 and its two-hundred day moving average price is $32.13.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The company had revenue of $564.50 million for the quarter, compared to analyst estimates of $555.80 million. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company earned $0.62 earnings per share. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. On average, research analysts expect that Enovis Corporation will post 2.79 EPS for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.